Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma
Kaishun Hu,Dan Liao,Wenjing Wu,An-Jia Han,Hui-Juan Shi,Fen Wang,Xin Wang,Li Zhong,Tingmei Duan,Yuanzhong Wu,Jingying Cao,Jianjun Tang,Yi Sang,Li Wang,Xiaobin Lv,Shuangbing Xu,Ru-Hua Zhang,Wu-Guo Deng,Sheng-Ping Li,Yi-Xin Zeng,Tiebang Kang
DOI: https://doi.org/10.18632/oncotarget.1816
2014-01-01
Oncotarget
Abstract:Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence and has a propensity for local invasion and early lung metastasis. However, the current therapies often result in chemoresistance, and a therapeutic target is not available in the clinic for osteosarcoma. Here, we report that BRD7 forms a complex with the anaphase-promoting complex/cyclosome (APC/C) and is degraded by APC/Ccdh1 and APC/Ccdc20 during the cell cycle. Moreover, BRD7 is a tumor suppressor in osteosarcoma, and the BRD7 mutant resistant to degradation by APC/C is more efficient than the wild-type protein at suppressing proliferation, colony formation, and tumor growth of osteosarcoma in vitro and in vivo. The combination of proTAME, an inhibitor of APC/C, with chemotherapeutic drugs efficiently targets osteosarcoma in vitro. Furthermore, there is a strong inverse correlation of protein levels between BRD7 and Cdh1 or Cdc20, and lower BRD7 expression is an indicator for poor prognosis in patients with osteosarcoma. Collectively, our results indicate that targeting the APC/C-BRD7 pathway may be a novel strategy for treating osteosarcoma.